Relationship between miR‑7 expression and treatment outcomes with gefitinib in non‑small cell lung cancer

Mou,Kun; Gu,Weiwei; Gu,Cuihua; Zhang,Jinzhong; Qwang,Wenjie; Ren,Gang; Tian,Jing

doi:10.3892/ol.2016.5290

Relationship between miR‑7 expression and treatment outcomes with gefitinib in non‑small cell lung cancer

Authors:
- Kun Mou
- Weiwei Gu
- Cuihua Gu
- Jinzhong Zhang
- Wenjie Qwang
- Gang Ren
- Jing Tian
View Affiliations

Affiliations: Department of Oncology, People's Hospital of Laiwu City, Laiwu Hospital Affiliated to Taishan Medical College, Laiwu, Shandong 271100, P.R. China, Department of Internal Medicine, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, Shandong 250117, P.R. China
Published online on: October 18, 2016 https://doi.org/10.3892/ol.2016.5290
Pages: 4613-4617
Copyright: © Mou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to assess the effects of gefitinib chemotherapy on the serum levels of miR‑7 in patients with non‑small cell lung cancer (NSCLC). A total of 126 patients were enrolled in the present study (stage I‑II, n=54 and stage III‑IV, n=72). Patients with stage I‑II NSCLC underwent surgery in combination with gefitinib chemotherapy, whereas only gefitinib chemotherapy was administered to patients with stage III‑IV disease. Serum levels of miR‑7 before and after treatment were measured with quantitative polymerase chain reaction using fluorogenic probes, and miR‑7 positivity and scoring in resected specimens were determined by immunohistochemistry. The number of miR‑7‑positive cases and the number of cases with higher miR‑7 scores were significantly lower among patients with stage I‑II NSCLC than those with stage III‑IV disease. Additionally, serum levels of miR‑7 before and after intervention were lower in stage I‑II than in stage III‑IV NSCLC cases. Serum levels of miR‑7 after treatment were significantly lower than those before intervention in the two groups. The treatment success rate was significantly higher in miR‑7‑negative patients than in miR‑7‑positive patients in the two patient groups. Adverse event rates in miR‑7‑negative and ‑positive patients were comparable between the groups. Among those with stage III‑IV NSCLC, the survival rate of miR‑7‑positive patients was significantly lower than that of miR‑7‑negative patients. Conversely, among those with I‑II NSCLC, the progression‑free survival and median survival time of miR‑7‑positive patients were significantly lower than those of miR‑7‑negative patients. Our findings suggest that serum and expression levels of miR‑7 in the tissue were closely associated with tumor staging and the therapeutic effects of gefitinib in NSCLC.

View Figures

View References

1	Yung KW, Yung TT, Chung CY, Tong GT, Liu Y, Henderson J, Welbeck D and Oseni S: Principles of cancer staging. Asian Pac J Surg Oncol. 1:1–16. 2015.
2	Zheng YF, Tan LK, Tan BH, Sterling H and Kane R: Principles of surgical oncology. Asian Pac J Surg Oncol. 1:17–26. 2015.
3	Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol. 21:2237–2246. 2003. View Article : Google Scholar : PubMed/NCBI
4	Cohen MH, Williams GA, Sridhara R, Chen G and Pazdur R: FDA drug approval summary: Gefitinib (ZD1839) (Iressa) tablets. Oncologist. 8:303–306. 2003. View Article : Google Scholar : PubMed/NCBI
5	Cufer T, Vrdoljak E, Gaafar R, Erensoy I and Pemberton K: SIGN Study Group: Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anticancer Drugs. 17:401–409. 2006. View Article : Google Scholar : PubMed/NCBI
6	Thatcher N, Chang A, Parikh P, Pereira J Rodrigues, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, et al: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 366:1527–1537. 2005. View Article : Google Scholar : PubMed/NCBI
7	Niho S, Ichinose Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K, Shinkai T, Jiang H, Nishiwaki Y and Fukuoka M: Results of a randomized Phase III study to compare the overall survival of gefitinib (IRESSA) versus docetaxel in Japanese patients with non-small-cell lung cancer who failed one or two chemotherapy regimens. J Clin Oncol. 25:2007.
8	Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, et al: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet. 372:1809–1818. 2008. View Article : Google Scholar : PubMed/NCBI
9	Lee DH, Park K, Kim JH, Lee JS, Shin SW, Kang JH, Ahn MJ, Ahn JS, Suh C and Kim SW: Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res. 16:1307–1314. 2010. View Article : Google Scholar : PubMed/NCBI
10	Kamil N, Kamil S, Ahmed SP, Ashraf R, Khurram M and Ali MO: Toxic effects of multiple anticancer drugs on skin. Pak J Pharm Sci. 23:7–14. 2010.PubMed/NCBI
11	Yang JC, Wu YL, Chan V, Kurnianda J, Nakagawa K, Saijo N, Fukuoka M, McWalter G, McCormack R and Mok TS: Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS). Lung Cancer. 83:174–181. 2014. View Article : Google Scholar : PubMed/NCBI
12	Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et al: West Japan Oncology Group: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar : PubMed/NCBI
13	Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, et al: North-East Japan Study Group: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
14	Guetz GD, Landre T, Uzzan B, Chouahnia K, Nicolas P and Morere JF: Is there a survival benefit of first-line epidermal growth factor receptor tyrosine-kinase inhibitor monotherapy versus chemotherapy in patients with advanced non-small-cell lung cancer?: A meta-analysis. Target Oncol. 11:41–47. 2016. View Article : Google Scholar : PubMed/NCBI
15	Xiong S, Zheng Y, Jiang P, Liu R, Liu X, Qian J, Gu J, Chang L, Ge D and Chu Y: PA28gamma emerges as a novel functional target of tumour suppressor microRNA-7 in non-small-cell lung cancer. Br J Cancer. 110:353–362. 2014. View Article : Google Scholar : PubMed/NCBI
16	Hu Y, Liao Z, Chen C, Qin N, Zheng J, Tian D, Li Y, Zhu S, Luo J and Xu L: Over-expressed microRNA-7 inhibits the growth of human lung cancer cells via suppressing CGGBP1 expression. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 30:125–130. 2014.(In Chinese). PubMed/NCBI
17	Zhang Z and Zhang R: Proteasome activator PA28 gamma regulates p53 by enhancing its MDM2-mediated degradation. EMBO J. 27:852–864. 2008. View Article : Google Scholar : PubMed/NCBI
18	Xu L, Wen Z, Zhou Y, Liu Z, Li Q, Fei G, Luo J and Ren T: MicroRNA-7-regulated TLR9 signaling-enhanced growth and metastatic potential of human lung cancer cells by altering the phosphoinositide-3-kinase, regulatory subunit 3/Akt pathway. Mol Biol Cell. 24:42–55. 2013. View Article : Google Scholar : PubMed/NCBI
19	Rai K, Takigawa N, Ito S, Kashihara H, Ichihara E, Yasuda T, Shimizu K, Tanimoto M and Kiura K: Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells. Mol Cancer Ther. 10:1720–1727. 2011. View Article : Google Scholar : PubMed/NCBI